EX-10.1 4 ea166170ex10-1_relmadather.htm EXCHANGE AGREEMENT BETWEEN RELMADA THERAPEUTICS, INC., AND VENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P., VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P., VHCP CO-INVESTMENT HOLDINGS II, LLC, VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P., AND VHCP CO-INVESTME

Exhibit 10.1

 

September 21, 2022

 

Relmada Therapeutics, Inc.

2222 Ponce de Leon, Floor 3

Coral Gables, FL 33134

 

Re:Section 3(a)(9) Exchange Agreement

 

Ladies and Gentlemen:

 

This letter agreement (the “Agreement”) confirms the agreement of Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to which the Stockholders have agreed to exchange an aggregate of 1,452,016 shares (the “Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), beneficially owned by the Stockholders in consideration for one or more Common Stock purchase warrants in the form attached hereto as Exhibit A (each a “Warrant”) to purchase an aggregate of 1,452,016 shares of Common Stock (the “Warrant Shares”) on the terms specified below.

 

In consideration of the foregoing, the Company and the Stockholders agree as follows:

 

(1) No later than the close of business on the first day after the date hereof on which The Nasdaq Stock Market is open for trading (a “Trading Day”), or such other date as mutually agreed upon by the parties of this Agreement (the “Closing Date”), and subject to the satisfaction or waiver of the conditions set forth herein, the Stockholders shall exchange the Shares for the Warrants (the “Exchange”) in the respective amounts listed on Schedule I. The Exchange shall be consummated pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). On or prior to the Closing Date: (a) the Stockholders shall jointly and irrevocably instruct their broker to transfer the Shares through the Deposit Withdrawal at Custodian (“DWAC”) system to Empire Stock Transfer Inc. (the “Transfer Agent”); (b) the Company and the Stockholders shall jointly and irrevocably instruct the Transfer Agent to take such Shares and register them in the name of the Company; and (c) the Company shall issue and deliver to the Stockholders the Warrants exercisable for the Warrant Shares, in the amounts and in the names set forth on Schedule I and shall instruct the Transfer Agent to reserve 1,452,016 shares of Common Stock, issuable upon the exercise of the Warrants.

 

(2) The Company represents and warrants to each Stockholder as follows:

 

(a) Neither the Company nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of the Securities Act and the rules and regulations of the Commission promulgated thereunder) for soliciting the Exchange. Assuming the representations and warranties of the Stockholders contained herein are true and complete, the Exchange will qualify for the registration exemption contained in Section 3(a)(9) of the Securities Act.

 

(b) It has the requisite corporate power and authority and power to enter into this Agreement and to consummate the Exchange, and such transactions shall not contravene any contractual, regulatory, statutory or other obligation or restriction applicable to the Company.

 

(c) It has reserved a sufficient number of shares of Common Stock as may be necessary to fully permit the exercise of the Warrants as of the date of issuance and the issuance of the Warrant Shares, without regard to any adjustment provisions or beneficial ownership limits set forth in the Warrant.

 

 

 

 

(3) Each Stockholder, as to itself only, represents and warrants to the Company as follows:

 

(a) It has the requisite power and authority to enter into this Agreement and consummate the Exchange and such transactions will not contravene any contractual, regulatory, statutory or other obligation or restriction applicable to such Stockholder.

 

(b) It is the record and beneficial owner of, and has valid and marketable title to, the Shares being exchanged by it pursuant to this Agreement, free and clear of any lien, pledge, restriction or other encumbrance (other than restrictions arising pursuant to applicable securities laws), and has the absolute and unrestricted right, power and capacity to surrender and exchange the Shares being exchanged by it pursuant to this Agreement, free and clear of any lien, pledge, restriction or other encumbrance. It is not a party to or bound by, and the Shares being exchanged by it pursuant to this Agreement are not subject to, any agreement, understanding or other arrangement (i) granting any option, warrant or right of first refusal with respect to such Shares to any person, (ii) restricting its right to surrender and exchange such Shares as contemplated by this Agreement, or (iii) restricting any other of its rights with respect to such Shares, and the Stockholders have received no additional consideration for the Shares other than Pre-funded Warrants.

 

(c) Neither it nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) and the rules and regulations of the Commission promulgated thereunder) for soliciting the Exchange.

 

(4) This agreement, and any action or proceeding arising out of or relating to this agreement, shall be exclusively governed by the laws of the State of New York.

 

(5) In the event that any part of this agreement is declared by any court or other judicial or administrative body to be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this agreement shall remain in full force and effect. In such an event, the Stockholders and the Company shall endeavor in good faith negotiations to modify this agreement so as to affect the original intent of the parties as closely as possible.

 

(6) This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. Each of the undersigned parties hereto acknowledge and agree that this Agreement may be executed by electronic signature, which shall have the same legal force and effect as a handwritten signature.

 

[SIGNATURE PAGE FOLLOWS]

 

2

 

 

Please sign to acknowledge agreement with the above terms and return to the undersigned.

 

  Common Stockholder:
     
  Venrock Healthcare Capital Partners EG, L.P.
  By: VHCP Management EG, LLC, its general partner
     
  By: /s/ Nimish Shah
  Name: Nimish Shah
  Title: Authorized Signatory
     
  Venrock Healthcare Capital Partners II, L.P.
  By: VHCP Management II, LLC, its general partner
  By: VR Advisor, LLC, its manager
     
  By: /s/ Nimish Shah
  Name:  Nimish Shah
  Title: Authorized Signatory
     
  VHCP Co-Investment Holdings II, LLC
  By: VHCP Management II, LLC, its general partner
  By: VR Advisor, LLC, its manager
     
  By: /s/ Nimish Shah
  Name: Nimish Shah
  Title: Authorized Signatory
     
  Venrock Healthcare Capital Partners III, L.P.
  By: VHCP Management III, LLC, its general partner
  By: VR Advisor, LLC, its manager
     
  By: /s/ Nimish Shah
  Name: Nimish Shah
  Title: Authorized Signatory
     
  VHCP Co-Investment Holdings III, LLC
  By: VHCP Management III, LLC, its manager
  By: VR Advisor, LLC, its manager
     
  By: /s/ Nimish Shah
  Name: Nimish Shah
  Title: Authorized Signatory

 

Signature Page to Warrant Exchange Agreement

 

3

 

 

  Acknowledged and agreed to:
     
  Relmada Therapeutics, Inc.
     
  By: /s/ Maged Shenouda
  Name:  Maged Shenouda
  Title: Chief Financial Officer

 

Signature Page to Warrant Exchange Agreement

 

4

 

 

SCHEDULE I 

 

Exchanging Stockholder  Shares to be
Exchange
   Warrant
Shares
 
Venrock Healthcare Capital Partners EG, L.P.   590,912    590,912 
Venrock Healthcare Capital Partners II, L.P.   174,214    174,214 
VHCP Co-Investment Holdings II, LLC   70,620    70,620 
Venrock Healthcare Capital Partners III, L.P.   560,238    560,238 
VHCP Co-Investment Holdings III, LLC   56,032    56,032 

 

 

 

 

EXHIBIT A

 

FORM OF WARRANT TO PURCHASE COMMON STOCK